Mirum Pharmaceuticals (NASDAQ:MIRM) Director Laura Brege Sells 14,167 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Laura Brege sold 14,167 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This trade represents a 47.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded up $0.66 during trading on Friday, hitting $93.99. The stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12 month low of $63.23 and a 12 month high of $130.00. The firm has a market cap of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75. The business’s 50-day moving average is $88.79 and its 200 day moving average is $98.41.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The business had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. During the same period in the prior year, the business posted $0.05 EPS. Mirum Pharmaceuticals’s quarterly revenue was up 39.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday, August 27th. Citizens Jmp lifted their target price on shares of Mirum Pharmaceuticals from $144.00 to $167.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 4th. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Cantor Fitzgerald boosted their price target on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Weiss Ratings lowered shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $155.56.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ABS Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at about $245,847,000. Integrated Wealth Concepts LLC purchased a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at about $27,000. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals in the 2nd quarter worth approximately $44,000. State of Wyoming bought a new stake in Mirum Pharmaceuticals in the 2nd quarter worth approximately $52,000. Finally, Fifth Third Bancorp bought a new stake in Mirum Pharmaceuticals in the 1st quarter worth approximately $56,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.